生物技术公司 Prothena 未达到收入目标，但尽管季度亏损，但仍获得“买入”评级。 Biotech firm Prothena misses revenue targets but gets a "buy" rating despite quarterly losses.

生物科技公司Prothena(NASDAQ:PRTA)击败了Q3 EPS的估计数,但未能达到收入目标,年收入下降98.9%。 Biotech firm Prothena (NASDAQ: PRTA) beat Q3 EPS estimates but missed revenue targets, with revenue down 98.9% year-over-year. 尽管净利润和股本回报为负数, HC Wainwright重申“买入”评级为84.00美元的价格目标, Despite a negative net margin and return on equity, HC Wainwright reiterates a "buy" rating with an $84.00 price target, indicating a 370.85% potential upside. Prothena的重点是治疗老年痴呆症和帕金森氏症等与蛋白质紊乱相关的疾病。 Prothena focuses on therapies for protein dysregulation-related diseases like Alzheimer's and Parkinson's. 星期三股票交易额为17.84美元。 Shares traded at $17.84 on Wednesday.